Membrane leakage induced by dynorphins  by Hugonin, Loïc et al.
FEBS Letters 580 (2006) 3201–3205Membrane leakage induced by dynorphins
Loı¨c Hugonina, Vladana Vukojevic´b, Georgy Bakalkinb, Astrid Gra¨slunda,*
a Department of Biochemistry and Biophysics, Arrhenius Laboratories, Stockholm University, S-10691 Stockholm, Sweden
b Section of Alcohol and Drug Dependence Research, Department of Clinical Neuroscience, Karolinska Institute, S-17176 Stockholm, Sweden
Received 6 December 2005; revised 24 April 2006; accepted 25 April 2006
Available online 4 May 2006
Edited by Maurice MontalAbstract Dynorphins, endogeneous opioid peptides, function as
ligands to the opioid kappa receptors and induce non-opioid exci-
totoxic eﬀects. Here we show that big dynorphin and dynorphin
A, but not dynorphin B, cause leakage eﬀects in large unilamellar
phospholipid vesicles (LUVs). The eﬀects parallel the previously
studied potency of dynorphins to translocate through biological
membranes. Calcein leakage caused by dynorphin A from LUVs
with varying POPG/POPC molar ratios was promoted by high-
er phospholipid headgroup charges, suggesting that electrostatic
interactions are important for the eﬀects. A possibility that
dynorphins generate non-opioid excitatory eﬀects by inducing
perturbations in the lipid bilayer of the plasma membrane is
discussed.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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leakage1. Introduction
The endogenous dynorphin peptides including dynorphin A
1–17 (Dyn A), dynorphin B (Dyn B) and big dynorphin (Big
Dyn), which consists of Dyn A and Dyn B sequences, are li-
gands for j-opioid receptors. They are synthesized in the stri-
atum, amygdala, hippocampus and other brain structures and
also in the spinal cord [1–8]. Consistent with their anatomical
localization, these peptides play a role in the modulation of re-
ward induced by intake of addictive substances, motor control,
stress response, memory acquisition and pain processing
[9–12].
Several actions of Dyn A and Big Dyn have been found to
be insensitive to the general opioid antagonist naloxone and
the selective j-antagonist nor-binaltorphimine [12–15]. The
non-opioid excitotoxic eﬀects of the synthetic and endogenous
Dyn A and Big Dyn can result in neurodegeneration and neu-
ronal death and are relevant for pathophysiological processes
such as chronic neuropathic pain and spinal cord and brain in-
jury [13,16–20]. Non-opioid dynorphin actions can be blockedAbbreviations: CPP, cell penetrating peptide; Big Dyn, big dynorphin;
Dyn A, Dynorphin A; Dyn B, Dynorphin B; LUVs, large unilamellar
phospholipid vesicles; POPC, 1-palmitoyl-2-oleoyl-phosphatidylcho-
line; POPG, 1-palmitoyl-2-oleoyl-phosphatidylglycerol
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doi:10.1016/j.febslet.2006.04.078by antagonists of the N-methyl-D-aspartate (NMDA) or al-
pha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate
(AMPA) glutamate receptors [12–16,19–21]. The glutamate
receptors are involved but do not apparently represent the pri-
mary targets for Dyn A and Big Dyn. Cell imaging experi-
ments demonstrated that Dyn A can induce a time- and
dose-dependent increase in intra-neuronal calcium concen-
tration through a non-opioid [22], non-glutamate receptor
mediated mechanism [23]. This mechanism may underlie non-
opioid neuropathological eﬀects of dynorphins.
We recently demonstrated that dynorphins share common
properties with cell penetrating peptides (CPPs) [24]. CPPs
are short, 5–35 amino acid peptides capable to translocate
across the cell plasma membrane without a chiral receptor
[25]. Recent studies indicate that CPPs may be transported
into cells through macropinocytosis, a form of endocytosis
[26]. Macropinocytosis may operate in parallel with the direct
translocation of these peptides across the plasma membrane
[27,28]. Several mechanisms have been proposed to explain di-
rect CPP translocation including pore formation [29], carpet
[29,30], membrane-thinning [31] or inverted micelles models
[32,33]. Similarly to CPPs, Dyn A and Big Dyn can translocate
across plasma membranes of live neurons and non-neuronal
cells [24]. Big Dyn has a much higher potency to penetrate than
Dyn A, which is similar in this respect to a prototypical CPP
transportan10. Dyn B and the central 22-amino acid Big
Dyn fragment did not penetrate into cells [24]. Translocation
of dynorphins into cells followed by their interactions with
intracellular targets was suggested as an evolutionary ancient
mechanism of intercellular communication and signal trans-
duction relevant for the non-opioid actions of these peptides.
The mechanisms of dynorphin transport across the plasma
membrane are unknown. One possibility is that dynorphins
can make transient pores in the lipid bilayer or induce mem-
brane perturbations allowing them to translocate into cells.
To test this hypothesis we investigated the interactions of
dynorphins with phospholipid membranes in the present
study. Peptide interactions with large unilamellar phospholipid
vesicles (LUVs) of varying surface charge densities were eval-
uated using ﬂuorescence spectroscopic methods. The mem-
brane perturbation eﬀects of the peptides were assessed by
calcein leakage experiments.2. Materials and methods
2.1. Materials
Dyn A was produced by Neosystem Laboratoire, Strasbourg. The
identity and purity was controlled by amino acid, mass spectral and






























Fig. 1. (A) Calcein leakage from LUVs, induced by the peptides: Dyn
A (s), Big Dyn (d), Dyn B (j) and melittin (h). Increasing
concentrations of the peptides were added to LUV samples, composed
of 100 lM phospholipids, mixed as POPG/POPC [30/70]. The LUVs
had 70 mM calcein entrapped before adding the peptide. The % calcein
release after 10 min was plotted as a function of total peptide-to-lipid
molar ratio, P/L. The solvent was 50 mM phosphate buﬀer (pH 7.2).
The calcein ﬂuorescence was recorded at an ambient temperature
(25 C). (B) Time-dependence of calcein leakage due to addition of
peptides at P/L = 0.05, with other conditions as in A.
Table 1
Amino acid sequences of the studied peptides
Peptide Sequence Charge at pH 7.0
Dyn A YGGFLRRIRPKLKWDNQ +4
Dyn B YGGFLRRQFKVVT +3
Big Dyn YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT +9
The peptides have native N- and C-termini.
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University. The peptides were not modiﬁed in the termini. The peptides
were puriﬁed by reversed-phase chromatography on Vydac C18 218
TP 1022 and Sephasil C8 columns in a 0.1% triﬂuoroacetic acid aceto-
nitrile/water solvent system and ﬁnally by gel ﬁltration on a Superdex
column in 1 M acetic acid. They were analyzed by analytical reversed-
phase chromatography and matrix-assisted laser desorption ioniza-
tion-time of ﬂight mass spectrometry (MALDI-TOF MS). Purity
was determined by integration of the UV peak at 215 nm. The purity
of all peptides was >98%. Melittin from the venom of honeybee (Apis
mellifera) was obtained from Sigma. 1-Palmitoyl-2-oleoyl-phosphati-
dylcholine (POPC), and 1-palmitoyl-2-oleoyl-phosphatidyl-glycerol
(POPG) were purchased from Avanti Polar Lipids, Alabaster, of the
best quality, and used without further puriﬁcation. Calcein, a ﬂuores-
cein derivative (C30H26N2O13,Mw = 622.5 g/mol), was purchased from
Molecular Probes, The Netherlands.
2.2. Determination of peptide concentrations
The concentration of peptides in aqueous stock solutions was deter-
mined spectrophotometrically at k = 280 nm on a CARY 4 spectro-
photometer. A molar absorptivity at 280 nm of 5690 M1 cm1 for
one Trp and 1280 M1 cm1 for one Tyr residue was applied in the
calculations [34].
2.3. Preparation of large unilamellar vesicles
LUVs were prepared by initially dissolving the phospholipids at the
desired concentration (with the chosen POPG/POPC molar ratio) in a
chloroform/ethanol mixture, to ensure the complete mixing of the com-
ponents, and then removing the solvent by placing the sample under
N2 (g) until the lipids were completely dried. The dried lipids were dis-
persed in 50 mM potassium phosphate buﬀer (pH 7.2). The dispersion
was run through a freeze–thaw cycle ﬁve times and then passed
through two polycarbonate ﬁlters (0.1 lm pore size) 20 times in an
Avanti manual extruder.
2.4. Calcein leakage
LUVs with entrapped calcein were prepared by hydrating a dried li-
pid ﬁlm of the desired composition with 70 mM calcein present in the
buﬀer (ﬁnal pH was adjusted to 7.2 by addition of NaOH from a 10 M
stock solution). Calcein not entrapped was separated from the LUVs
on a Sephadex-G25 column. Fluorescence was measured on a Horiba
Jobin Yvon Fluorolog-3 spectrometer using the DataMax operating
software. The ﬂuorescence from calcein at 70 mM concentration was
low due to self-quenching, but increased considerably upon dilution.
Increasing concentrations of peptides were added to LUVs composed
of 100 lM phospholipid mixtures of deﬁned POPG/POPC content.
After 10 min incubation at 25 C, the release of calcein from the LUVs
was monitored by an increase in the ﬂuorescence intensity. The ﬂuores-
cence intensity was measured at 520 nm (excitation at 490 nm).
The maximum ﬂuorescence intensity (100% leakage) was determined
by lysing the vesicles with a 10% (w/v) solution of the detergent Triton
X-100. The percent leakage value was then calculated according to the
following equation:
percent leakage ¼ 100 F  F 0
Fmax  F 0
 
% ð1Þ
where F0 represents the ﬂuorescence intensity of the intact vesicle, F
and Fmax the intensity before and after the addition of the detergent,
respectively. The experiments were generally repeated at least three
times with diﬀerent preparations of vesicles. The experimental uncer-
tainty was estimated to ±5% of the measured value.3. Results
3.1. Leakage of Calcein from LUVs
The membrane perturbation eﬀects of the peptides were
investigated through LUV calcein leakage experiments, evalu-
ated using Eq. 1. The peptides studied here had native N- and
C-termini. In the absence of the peptide, no leakage of calcein
from the LUVs was observed. Fig. 1A shows the % leakage in-
duced by the peptides from LUVs with partially negatively
charged headgroups, POPG/POPC (30/70), after 10 min incu-
bation at 25 C. Both Big Dyn and Dyn A cause a substantial
degree of leakage and for both peptides the leakage is almost
satured at P/L = 0.05 corresponding to 5 lM peptide concen-
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A (70% and 40%, respectively). Dyn B induced no leakage. The
pore-forming peptide melittin was used as a comparison, and
was found to induce almost 100% leakage already at a P/
L  0.02. The time dependence study of calcein leakage from
the vesicles at a P/L ratio of 0.05 (Fig. 1B) indicated that after
10 min almost no further release of calcein was observed. Con-
sequently the percentage of leakage after 10 min presented in
Fig. 1 should approximately represent the ﬁnal stage at each
peptide concentration.
In another series of experiments the inﬂuence of LUV head-
group charges was studied for Dyn A. The leakage caused by
Dyn A interaction from LUVs of diﬀerent POPG/POPC molar
ratio compositions is presented in Fig. 2. The peptide causes
leakage (40%) in the zwitterionic membrane POPC LUVs, sim-
ilar to the charged LUVs with POPG/POPC (30/70). Between
P/L ratios 0 and 0.1 the leakage is less prominent with the
zwitterionic LUVs. In the more highly charged LUVs with
POPG/POPC (50/50), Dyn A causes a higher degree of leakage
(80%). The data suggest a sigmoidal dependency of leakage
intensity versus Dyn A concentration for the zwitterionic
POPC LUVs (Fig. 2), possibly related to membrane-mediated
cooperative interactions leading to pore formation [35]. The
dependence on phospholipid headgroup charge shows that
electrostatic interactions aﬀect the processes. When the surface
charge on the membrane is increased, the peptide–membrane
interactions are apparently increased, and the leakage proﬁle
becomes hyperbolic.
Previous studies have shown that the dynorphins interact
strongly with small unilamellar phospholipid vesicles (SUVs),
however with only a surprisingly weak induction of secondary
structure [24]. We have here observed similar weak structure
induction by CD spectroscopy for the dynorphins using the
LUV membrane model systems (data not shown). This is in
contrast to most amphipathic peptides [36], and indeed a sim-
ple helical wheel study shows very little amphipathic character













Fig. 2. Dyn A-induced leakage from LUVs, composed of 250 lM
phospholipids of diﬀerent POPG/POPC molar ratios: POPG/POPC [0/
100] (s), POPG/POPC [30/70] (h), POPG/POPC [50/50] (d).The
LUVs had 70 mM calcein entrapped before adding the peptide. The %
calcein release after 10 min incubation was plotted as a function of the
total peptide-to-lipid molar ratio, P/L. The solvent was 50 mM
phosphate buﬀer (pH 7.2). The calcein ﬂuorescence was recorded at
an ambient temperature (25 C).4. Discussion
The dynorphins are similar to several groups of CPPs in the
high content of hydrophobic and basic amino acids (Table 1).
The generally low cytotoxic eﬀects of some CPPs, such as
penetratin peptide (pAntp), distinguish them from transloca-
ting cationic antimicrobial and lytic peptides, such as melittin,
which have strong eﬀects on the membrane integrity causing
leakage eﬀects and have a powerful hemolytic activity [37].
However, certain other CPPs, such as the model amphipathic
peptide (MAP) and transportan, exhibit membrane toxicity
in cells [38]. Our previous studies have established that Big
Dyn and to a lesser extent Dyn A, but not Dyn B, eﬃciently
translocate through cell membranes of neuronal and non-
neuronal cells [24]. Big Dyn and Dyn A, but not Dyn B, also
exhibit cytotoxicity in non-neuronal and neuronal cells [39].
The present study of the dynorphins in membrane model sys-
tems was undertaken to elucidate the molecular mechanisms
by which the dynorphins exert their non-opioid activities.
The results show that Big Dyn and Dyn A, but not Dyn B,
cause perturbations and leakage in a membrane model system
composed of phospholipid LUVs. The higher membrane-per-
turbing potency of Big Dyn compared to Dyn A may be due
to its higher positive charge (Table 1). The low potency of
Dyn B may be due to its smaller positive charge, or possibly
its shorter length compared to the other dynorphins. The fact
that Dyn B has the highest percentage of hydrophobic residues
of the three peptides apparently does not make it more potent
as a membrane-perturbing agent.
The calcein leakage from LUVs could be induced either by
making channels in them (pore-formation) or by lysis of the
vesicles. The latter is unlikely since the vesicles exhibit only
partial leakage in presence of high concentrations of either
Big Dyn or Dyn A. Several other studies on peptides interact-
ing with membranes have reported similar saturation eﬀects,
yielding leakage curves which seem to level oﬀ as a function
of time at constant peptide concentration [40,41]. This
phenomenon has been explained in terms of transient pore
formation with a nucleation step during an initial bilayer per-
turbation period, followed by a transient restabilization of the
peptide/lipid bilayer structure, which gives rise to the observed
leveling oﬀ of the spontaneous leakage [42]. The kinetics of
leakage of Big Dyn and Dyn A can be explained in similar
terms. Melittin is known to make transient or more permanent
pores in phospholipid membranes [43,44]. Big Dyn and Dyn A
may cause similar eﬀects although they are less potent in their
membrane perturbation.
The most important observation in the present study is that
the potency to translocate through cell membranes [24], the
cytotoxicity [37] and the degree of leakage from LUVs induced
by the dynorphins, all follow the same order and seem to be
correlated when comparing the three peptides. Consistent with
these in vitro data, Big Dyn administered intrathecally into
mice induces characteristic nociceptive behavior insensitive to
naloxone, whereas Dyn A was 100-fold less potent and Dyn
B was inactive [19]. These results suggest a close molecular
connection between the phenomena, which hypothetically in-
volves the formation of dynorphin-induced transient mem-
brane pores, similar to those induced by melittin.
The high positive charge has been demonstrated to be
important for the binding of CPPs to negatively charged gly-
3204 L. Hugonin et al. / FEBS Letters 580 (2006) 3201–3205cosaminoglycans on the plasma membrane [26]. This may be
important also for the dynorphin activities. The study of Dyn
A interaction with LUVs of diﬀerent POPG/POPC composi-
tions suggest that the membrane interaction is not only due
to charge interactions, since the peptide causes leakage also
in vesicles with zwitterionic headgroups. However, higher
membrane charge density results in higher degree of leakage
as has been observed also for other positively charged pep-
tides [41]. Consequently electrostatic but also hydrophobic
interactions are important for the binding of Dyn A to
membranes.
In conclusion, the mechanism of membrane leakage induced
by dynorphins is not yet understood on the molecular level but
there are indications that formation of pores is important. The
correlation between results obtained with phospholipid mem-
branes, on live cells in vitro [24,39] and in animal experiments
[19,20] suggests that dynorphins induce non-opioid excitatory
eﬀects through transient pore formation or perturbations of
the phospholipid bilayer in the plasma membrane. These pores
or perturbations may allow transient redistribution of calcium,
sodium and potassium ions between cells and the medium
leading to neuronal depolarization. Observations that Dyn A
increases intracellular calcium ion concentration in rat cortical
neurons through a non-opioid [22], non-glutamate receptor
mediated mechanism [23], support this hypothesis.
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